TGTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
TG THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$53.30−0.67 (-1.24%)
Close on Oct 19, 2026
- Market cap
- $8.38B
- P/E (TTM)
- 19.5
- Dividend yield
- –
Tg Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Tg Therapeutics | Industry median |
|---|---|---|
| Market Cap | $8.16B | $166.30M |
| Enterprise Value | $8.29B | $88.19M |
| PE Ratio | 19.45 | 20.44 |
| PS Ratio | 10.20 | 3.65 |
| PB Ratio | 13.51 | 2.03 |
| P/TBV Ratio | 13.51 | 2.29 |
| P/FCF Ratio | 469.29 | 17.44 |
| P/OCF Ratio | 456.40 | 12.98 |
Enterprise value
| Measure | Tg Therapeutics | Industry median |
|---|---|---|
| EV / Sales | 10.37 | 2.51 |
| EV / EBITDA | 60.77 | 14.65 |
| EV / EBIT | 60.82 | 19.00 |
| EV / FCF | 476.94 | 20.86 |
Income (trailing twelve months)
| Measure | Tg Therapeutics | Industry median |
|---|---|---|
| Revenue | $799.54M | $58.34M |
| Gross Profit | $658.60M | $105.94M |
| Operating Income | $136.33M | -$21.40M |
| Pretax Income | $101.60M | -$14.34M |
| Net Income | $441.49M | -$22.46M |
| EBITDA | $136.45M | -$16.91M |
| EPS (Diluted) | $2.74 | -$0.83 |
Margins
| Measure | Tg Therapeutics | Industry median |
|---|---|---|
| Gross Margin | 82.4% | 52.9% |
| Operating Margin | 17.1% | -44.0% |
| Pretax Margin | 12.7% | -13.3% |
| Profit Margin | 55.2% | -40.2% |
| EBITDA Margin | 17.1% | -30.2% |
| FCF Margin | 2.17% | -9.27% |
Returns
| Measure | Tg Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | 100.3% | -53.2% |
| Return on Assets (ROA) | 37.7% | -40.9% |
| Return on Invested Capital (ROIC) | 27.8% | -32.4% |
| Return on Capital Employed (ROCE) | 9.94% | -38.1% |
Growth
| Measure | Tg Therapeutics | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 76.1% | 5.96% |
| Net Income Growth (YoY) | 630.2% | -35.2% |
| EPS Growth (YoY) | 640.5% | -26.2% |
| Revenue Growth (3Y CAGR) | 504.9% | 2.25% |
| Revenue Growth (5Y CAGR) | 426.7% | 6.48% |
Balance sheet
| Measure | Tg Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $612.30M | $61.43M |
| Total Debt | $745.39M | $118.52M |
| Net Cash (Debt) | -$133.09M | $15.35M |
| Net Cash Per Share | -$0.87 | $0.66 |
| Equity (Book Value) | $604.08M | $49.09M |
| Book Value Per Share | $3.95 | $1.37 |
| Tangible Book Value | $604.08M | $23.52M |
| Working Capital | $877.19M | $76.81M |
Financial position
| Measure | Tg Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 4.27 | 3.34 |
| Quick Ratio | 3.78 | 2.44 |
| Debt / Equity | 1.23 | 0.52 |
| Debt / EBITDA | 5.46 | 3.44 |
| Debt / FCF | 42.88 | 4.89 |
| Net Debt / EBITDA | 0.98 | 2.36 |
| Interest Coverage | 3.64 | -6.26 |
Cash flow (trailing twelve months)
| Measure | Tg Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | $17.88M | -$12.35M |
| Capital Expenditures | -$491.00K | -$1.08M |
| Free Cash Flow | $17.39M | -$20.22M |
| FCF Per Share | $0.11 | -$0.42 |
Efficiency
| Measure | Tg Therapeutics | Industry median |
|---|---|---|
| Asset Turnover | 0.68 | 0.39 |
| Inventory Turnover | 0.93 | 2.70 |
| Revenue Per Employee | $2.00M | $404.87K |
| Profits Per Employee | $1.11M | -$703.34K |
| Employee Count | 399 | 74 |
Dividends and yields
| Measure | Tg Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | 5.41% | -23.3% |
| FCF Yield | 0.21% | -8.72% |
| Buyback Yield | 2.18% | -0.59% |
| Shareholder Yield | 2.18% | 0.00% |
Shares
| Measure | Tg Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 153,069,000 | 58,127,000 |
| Shares Change (YoY) | -1.33% | 10.9% |
| Shares Change (QoQ) | -0.01% | 0.54% |
| Float | 128,466,000 | 49,136,700 |
| Shares Held by Insiders | 16.1% | 11.6% |
| Shares Held by Institutions | 72.6% | 59.4% |
Taxes
| Measure | Tg Therapeutics | Industry median |
|---|---|---|
| Income Tax | -$339.89M | $79.87K |
| Effective Tax Rate | -334.5% | 20.6% |
Scores
| Measure | Tg Therapeutics | Industry median |
|---|---|---|
| Graham Number | $15.60 | $18.73 |
| Graham Upside | -70.7% | -45.1% |
| Altman Z-Score | 5.23 | -0.22 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Tg Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.